Sucampo Pharmaceuticals’ (NASDAQ:SCMP) Neutral Rating Reiterated at Mizuho

Mizuho reaffirmed their neutral rating on shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) in a research note released on Wednesday, January 3rd, Marketbeat.com reports. Mizuho currently has a $18.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $14.00.

SCMP has been the subject of several other research reports. Zacks Investment Research raised shares of Sucampo Pharmaceuticals from a hold rating to a buy rating and set a $11.00 price objective for the company in a research report on Tuesday, October 17th. Nomura assumed coverage on shares of Sucampo Pharmaceuticals in a research report on Monday, December 18th. They issued a buy rating and a $43.00 price objective for the company. UBS Group lowered their price target on shares of Sucampo Pharmaceuticals from $19.00 to $15.00 and set a buy rating for the company in a report on Thursday, October 12th. BidaskClub raised shares of Sucampo Pharmaceuticals from a hold rating to a buy rating in a report on Tuesday, December 5th. Finally, ValuEngine raised shares of Sucampo Pharmaceuticals from a hold rating to a buy rating in a report on Friday, December 1st. Six investment analysts have rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. Sucampo Pharmaceuticals has an average rating of Buy and a consensus target price of $21.58.

Sucampo Pharmaceuticals (NASDAQ SCMP) traded down $0.35 during trading hours on Wednesday, reaching $18.05. 1,562,916 shares of the company’s stock were exchanged, compared to its average volume of 4,243,397. The company has a debt-to-equity ratio of 7.37, a quick ratio of 4.46 and a current ratio of 5.11. The stock has a market capitalization of $851.38, a P/E ratio of -5.49, a P/E/G ratio of 5.07 and a beta of 1.45. Sucampo Pharmaceuticals has a 12 month low of $9.30 and a 12 month high of $18.75.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last released its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.25 by $0.02. Sucampo Pharmaceuticals had a negative net margin of 60.24% and a positive return on equity of 74.58%. The company had revenue of $61.27 million during the quarter, compared to analyst estimates of $58.05 million. During the same quarter in the prior year, the business earned $0.30 earnings per share. The business’s quarterly revenue was up 5.9% compared to the same quarter last year. research analysts anticipate that Sucampo Pharmaceuticals will post 1.12 earnings per share for the current year.

In other Sucampo Pharmaceuticals news, insider Peter A. Kiener sold 50,000 shares of the firm’s stock in a transaction on Thursday, December 7th. The shares were sold at an average price of $16.50, for a total transaction of $825,000.00. Following the completion of the transaction, the insider now directly owns 52,023 shares of the company’s stock, valued at approximately $858,379.50. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 4.13% of the stock is owned by company insiders.

A number of hedge funds have recently made changes to their positions in SCMP. HPM Partners LLC bought a new position in shares of Sucampo Pharmaceuticals in the 2nd quarter worth about $1,307,000. Trexquant Investment LP bought a new position in shares of Sucampo Pharmaceuticals in the 3rd quarter worth about $122,000. Nine Chapters Capital Management LLC bought a new position in shares of Sucampo Pharmaceuticals in the 3rd quarter worth about $127,000. JPMorgan Chase & Co. bought a new position in shares of Sucampo Pharmaceuticals in the 2nd quarter worth about $117,000. Finally, Aperio Group LLC bought a new position in shares of Sucampo Pharmaceuticals in the 3rd quarter worth about $137,000. 65.29% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by BBNS and is the sole property of of BBNS. If you are reading this news story on another domain, it was stolen and republished in violation of United States and international copyright & trademark laws. The correct version of this news story can be viewed at https://baseballnewssource.com/markets/sucampo-pharmaceuticals-scmp-neutral-rating-reiterated-at-mizuho/1808801.html.

Sucampo Pharmaceuticals Company Profile

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Analyst Recommendations for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with our FREE daily email newsletter.

 


Latest News

Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
Trade Rumor: Manny Machado Could Land With Yankees
Trade Rumor: Manny Machado Could Land With Yankees
Los Angeles Dodgers Acquire Scott Alexander as Part of Three Team Deal
Los Angeles Dodgers Acquire Scott Alexander as Part of Three Team Deal


Leave a Reply

 
© 2006-2018 BBNS.